AstraZeneca to upgrade US listing in ‘knock-back for London’
by Julia Kollewe and Lauren Almeida from on (#70CJS)
UK's biggest drugmaker will put its US shares on a par with its London-based stock but says HQ will stay in Cambridge
The UK's biggest drugmaker, AstraZeneca, has said it will list its shares directly on the New York Stock Exchange in a decision described as a knock-back for London".
The FTSE 100 company said its direct listing in New York would replace trading in its American depositary receipts (ADRs) - which give US investors exposure to a non-US company - on the Nasdaq.
Continue reading...